graft-versus-host disease

Fierce Pharma

FDA delays decision on Orca Bio’s cell therapy for blood cancers

The delay comes at a time when the biopharma industry is highly attuned to FDA actions on cell and gene therapies after a string of regulatory surprises.

Angus Liu Apr 1, 2026 8:00am

Fierce Pharma

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am

Equillium misses primary, key secondaries, plans approval filing

Mar 27, 2025 9:52am

Orca prepares to make market plunge after phase 3 win

Mar 17, 2025 7:00am

Concepts of medical examination and study of intestine microflora

MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing

Jan 9, 2025 5:18am

Viral protein suppresses graft vs. host disease in mice

Jul 19, 2024 5:30am